ext-generation sequencing to predict phenotypic drug sensitivity of tuberculosis: meta-analysis of diagnostic test accuracy
Not Applicable
- Conditions
- M. tuberculosis infection
- Registration Number
- JPRN-UMIN000049276
- Lead Sponsor
- Yokohama City University Hospital, Chemotherapy Center
- Brief Summary
See below: Yoichi Tagami, Nobuyuki Horita, Megumi Kaneko et al. J Infect Dis. 2023 Nov 8:jiad480. Whole-genome sequencing predicting phenotypic antitubercular drug resistance: meta-analysis
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 16821
Inclusion Criteria
Not provided
Exclusion Criteria
A number of isolates should be larger than 20.
Study & Design
- Study Type
- Others,meta-analysis etc
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Drugs of our interests are isoniazid, rifampicin, pyrazinamide, ethambutol, streptomycin, amikacin, kanamycin, para-amino-salicylic acid (PAS), capreomycin, levofloxacin, moxifloxacin, ofloxacin, ethionamide, protionamide, and cyclocerine. Combined evaluation of quinolones, first-line drugs, and second-line drugs will not be adopted. Diagnostic odds ratio (DOR), area under the curve (AUC) of summary receiver operating characteristics curve (SROC), estimated sensitivity, and specificity will be calculated.
- Secondary Outcome Measures
Name Time Method